Novo Nordisk Strikes Back on Multiple Fronts as Obesity Data and Market Access Converge
Despite record prescriptions, positive clinical data for oral Wegovy, and a landmark Medicare deal, Novo Nordisk stock has…
Novo Nordisk Retools Danish Factory as Wegovy Data Opens New Frontiers in Obesity Care
Novo Nordisk repurposes $1.2B factory for Wegovy as obesity franchise surges; oral pill captures 65% of new US…
Novo Nordisk Faces First Generic Challenge in Canada as Wegovy Oral Pill Dominates US Market
Novo Nordisk’s US Wegovy surges with 65% of new scripts, raising guidance, but Canadian Ozempic generic approval threatens…
Novo Nordisk’s Oral Wegovy Wins Patient Preference as Long-Term Efficacy Data Strengthens Case
84% of patients prefer Novo Nordisk’s oral Wegovy over Lilly’s pill, with 14x lower dropout rate. Phase 3…
Novo Nordisk Streamlines Operations as Oral Wegovy Data Reinforce Obesity Strategy
Novo Nordisk sells Parkinson’s candidate to focus on metabolic drugs; oral Wegovy shows 21.6% weight loss at 64…
Novo Nordisk Dual Obesity Data and Odense Retooling Signal Strategic Pivot
Novo Nordisk presents promising obesity trial results for high-dose Wegovy and oral semaglutide, while restructuring manufacturing in Odense…
Novo Nordisk Bets on Oral Pill and CagriSema to Reclaim Obesity Leadership After 60% Sell-Off
Novo Nordisk rallies on oral Wegovy’s 21.6% weight loss, bests Lilly; CagriSema submitted for US approval. Stock up…
Novo Nordisk’s Obesity Franchise Expands Reach as Comorbidity Data and Pipeline Catalysts Converge
Semaglutide reduces asthma exacerbations by 26% and migraine medication use by 7%. Stock rebounds 13% in 30 days;…
Novo Nordisk Scraps Rare-Disease Factory, Bets on Oral Obesity Pill and CagriSema to Revive Growth
Novo Nordisk pivots from rare diseases to obesity, scrapping a Danish plant and 400 jobs, as it races…
Novo Nordisk Redoubles Metabolic Efforts as Parkinson Divestiture and Analyst Upgrade Align
Danish drugmaker sells Parkinson cell therapy asset to focus on metabolic disease, as Hedgeye sees 52-117% upside and…
Novo Nordisk Sheds Stray Assets to Double Down on Obesity Pipeline as Oral Wegovy Gains Traction
Novo Nordisk offloads Parkinson’s cell therapy to focus on obesity and diabetes, with CagriSema pending US approval and…
Novo Nordisk Combines Direct-to-Patient Service with Analyst Optimism in Obesity Fight
Hedgeye sees up to 117% upside for Novo Nordisk as oral obesity pill prescriptions surge; home delivery via…